

Supplementary Material

Supplementary Table 1. ACMG/AMP criteria that were excluded from *TP53*-specific guidelines

Original ACMG/AMP criterion	Rationale for exclusion
PM3 For recessive disorders, detected in trans with a pathogenic variant.	Not relevant because LFS is not a recessive disorder, but rather a dominant disorder.
PM4 Protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants.	Not used due to limited available data.
PP2 Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease	Not applicable due to the high rate of benign missense variation in <i>TP53</i> .
PP4 Patient's phenotype or family history is highly specific for a disease with a single genetic etiology.	Already captured by the specifications of PS4, and thus cannot be used as independent evidence.
PP5 Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.	Not applicable following Sequence Variant Interpretation recommendations (Biesecker & Harrison, 2018).
BP1 Missense variant in a gene for which primarily truncating variants are known to cause disease.	Not relevant, as truncating variants account for only a portion of disease-causing variants in <i>TP53</i> and there are many pathogenic missense alleles.
BP3 In-frame deletions/insertions in a repetitive region without a known function.	Not used due to limited available data
BP5 Variant found in a case with an alternate molecular basis for disease.	Not used at this time as an individual could have multiple hereditary factors to explain a personal and/or family history of cancer. Therefore, having a known <i>ATM</i> pathogenic variant would not eliminate the possibility of also having a <i>TP53</i> pathogenic variant.
BP6 Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.	Not applicable following Sequence Variant Interpretation recommendations (Biesecker & Harrison, 2018).

Clinical criteria	<i>TP53</i> Carriers		Non-carriers		Risk Ratio	RR	95%-CI
	Events	Total	Events	Total			
Classic LFS	4	298	1	1160		15.57	[1.75; 138.79]
Chompret 2015	64	298	74	1160		3.37	[2.47; 4.59]

Supplementary Figure 1. Calculation of likelihood ratios of pathogenicity for a variant found in a proband meeting Classic LFS or only Chompret 2015 clinical criteria, using data from Ambry Genetics, where events corresponds to the number of *TP53* carriers or non-carriers meeting each of these clinical criteria

Supplementary Table 2. Likelihood ratios (LR) towards pathogenicity for a variant identified in a female individual with no cancer by age 60 for the specification of the BS2 criterion, using data from Ambry Genetics and GeneDx

Dataset	Ambry Genetics			GeneDx		
Individuals with no cancer by age 60 (n)	% <i>TP53</i> carriers (n/total N)	% Non-carriers (n/total N)	LR (95% CI)	% <i>TP53</i> carriers (n/total N)	% Non-carriers (n/total N)	LR (95% CI)
	12.38 (38/307)	18.62 (210/112)	0.66 (0.48; 0.92)	5.63 (8/142)	19.97 (18936/94807)	0.28 (0.14; 0.55)

Supplementary Table 3. Likelihood ratios (LR) towards pathogenicity estimated for the original ACMG/AMP PM5 criterion, based on amino acid (aa) residues observations of 493 non-functional and 1239 functional or supertrans variants from yeast transactivation assays

Number of occurrences of an aa in the dataset	Number of pathogenic variants at that aa	%	Number of benign variants at the same aa	%	LR (95% CI)
1	55	11.16	159	12.83	0.87 (0.66, 1.15)
2	52	10.55	45	3.63	2.90 (1.99, 4.24)
3	72	14.60	28	2.26	6.46 (4.26, 9.80)
4	72	14.60	10	0.81	18.09 (9.46, 34.61)
5	145	29.41	10	0.81	36.44 (19.46, 68.25)
6 or more	97	19.7	0.00	0.00	NA

Supplementary Table 4. Comparison of performance of functional assays against reference sets of assumed pathogenic and benign p53 missense variants based on clinical evidence

Given name to the functional assay	Matthews correlation coefficient
Kato LOF	0.94
Giacomelli LOF (etoposide) + DNE	0.88
Kotler LOF	0.77
Giacomelli LOF (etoposide)	0.73
Giacomelli DNE (etoposide)	0.70
Giacomelli LOF (nutlin)	0.34